Table 5. Quality indicators for Cohort studies.

Cohort study First Author, Year	Study design	Same mode of inclusion for intervention and control group	Enough F/U duration (>12 mionths)	Adjusted analysis for confounding variables	Mode of participants selection described	Potential important baseline differences	Report of loss of F/U	Reports of adverse events	Sample size pre-specified	Report of important baseline characteristics modification during F/U
Beta blockers and other antihypertensive agents
Wilmink [23] 2002	Cohort*	Yes	Yes	Yes	Yes	No	No	No	No		No
Lindholt [24] 2001	Cohort	No	Yes	Yes	No	No	No	No	No		No
Gadowski [25] 1994	Cohort	Yes	Yes	No	Yes	No	No	No	No		No
Leach [26] 1988	Cohort	Yes	Yes	No	Yes	No	Yes	Yes	No		No
Biancari [27] 2002	Cohort	Yes	Yes	No	Yes	No	Yes	Yes	No		No
Brady [34] 2004	Cohort	Yes	Yes	Yes	Yes	No	No	No	No		No
Anti-inflammatory
Schouten [30] 2006	Cohort	Yes	Yes	Yes	Yes	Yes	Yes	No	No		No
Sukhija [31] 2006	Cohort	Yes	Yes	No	No	No	No	No	No		No
Walton [32] 1999	Cohort	Yes	Yes	No	No	No	Yes	Yes	No		No

^*Same results for Wilmink 2002 Beta blockers, Ca channel blockers, diuretics and ACE inhibitors studies